1. Dutta R, Dubal PM, Svider PF et al. (2015). Sinonasal malignancies: a population-based analysis of site-specific incidence and survival. Laryngoscope, 125(11): 2491-2497. [DOI:10.1002/lary.25465]

2. Lund VJ, Howard DJ, Wei WI et al. (2007). Endoscopic resection of malignant tumours of the nose and sinuses. Am J Rhinol, 21(1): 89-94. [DOI:10.2500/ajr.2007.21.2957]

3. Schreiber A, Villaret AB, Maroldi R, et al. (2012). Fibrous dysplasia of the sinonasal tract and adjacent skull base. Curr Opin Otolaryngol Head Neck Surg, 20(1): 45-52. [DOI:10.1097/MOO.0b013e32834e901c]

4. Rao VM and El-Noueam KI (1998). Sinonasal imaging: anatomy and pathology. Radiol Clin North Am, 36(5): 921-939. [DOI:10.1016/S0033-8389(05)70069-5]

5. Turner JH and Reh DD (2012) Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head & neck, 34(6): 877-885. [DOI:10.1002/hed.21830]

6. Su SY, Kupferman ME, DeMonte F, et al. (2014). Endoscopic resection of sinonasal cancers. Curr Oncol Rep, 16(2): 369. [DOI:10.1007/s11912-013-0369-6]

7. Gore MR (2018) Survival in sinonasal and middle ear malignancies: a population-based study using the SEER 1973-2015 database. BMC Ear Nose Throat Disord. 18: 13. [DOI:10.1186/s12901-018-0061-4]

8. Amit M, Tam S, Abdelmeguid AS, et al. (2017). Role of adjuvant treatment in sinonasal mucosal melanoma. J Neurol Surg B Skull Base, 78(6): 512-518. [DOI:10.1055/s-0037-1604350]

9. Lewis JS Jr (2020). Sinonasal squamous cell carcinoma: A review with updates. Adv Anat Pathol, 27(3): 166-172.

10. Rimmer J, Lund VJ, Beale T, et al. (2014). Olfactory neuroblastoma: a 35-year experience and suggested follow-up protocol. Laryngoscope. 124(7): 1542-1549. [DOI:10.1002/lary.24562]

11. Leivo I (2016). Sinonasal adenocarcinoma: Update on classification, immunophenotype and molecular features. Head Neck Pathol. 10(1): 68-74. [DOI:10.1007/s12105-016-0694-9]

12. Nicolai P, Battaglia P, Bignami M, et al. (2008) Endoscopic surgery for malignant tumours of the sinonasal tract and adjacent skull base: a 10-year experience. Am J Rhinol, 22(3): 308-316. [DOI:10.2500/ajr.2008.22.3170]

13. Amit M, Abdelmeguid AS, Watcherporn T, et al. (2019). Induction chemotherapy response as a guide for treatment optimization in sinonasal undifferentiated carcinoma. J Clin Oncol, 37(6): 504-512. [DOI:10.1200/JCO.18.00353]

14. Jain S, Li Y, Kuan EC, et al. (2019). Prognostic Factors in Paranasal Sinus Squamous Cell Carcinoma and Adenocarcinoma: A SEER Database Analysis. J Neurol Surg B Skull Base, 80(3): 258-263. [DOI:10.1055/s-0038-1669420]

15. Hoppe BS, Stegman LD, Zelefsky MJ, et al. (2007). Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting - the MSKCC experience. Int J Radiat Oncol Biol Phys, 67(3): 691-702. [DOI:10.1016/j.ijrobp.2006.09.023]

16. Bishop AJ, Garden AS, Rosenthal DI, et al. (2016) Sinonasal undifferentiated carcinoma: outcomes following radiotherapy. Head Neck. 38(9): 1310-1316.

17. Topalian SL, Drake CG, Pardoll DM (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell, 27(4): 450-461. [DOI:10.1016/j.ccell.2015.03.001]

18. Ribas A and Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science, 359(6382): 1350-1355. [DOI:10.1126/science.aar4060]

19. Ferris RL (2015) Immunology and immunotherapy of head and neck cancer. J Clin Oncol, 33(29): 3293-3304. [DOI:10.1200/JCO.2015.61.1509]

20. Dogan S, Chute DJ, Xu B, et al. (2017) PD-L1 expression in non-keratinizing carcinomas of the sinonasal tract. Am J Surg Pathol, 41(6): 788-798.

21. Amit M, Abdelmeguid AS, Watcherporn T, et al. (2019) Neoadjuvant chemotherapy for advanced sinonasal cancers. Cancer, 125(5): 770-777.

22. Hanna GJ, Genovesi D, Lorch JH (2021) Neoadjuvant therapy for head and neck squamous cell carcinoma. Cancers (Basel), 13(2): 275.

23. Galluzzi L, Buqué A, Kepp O, et al. (2017) Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol, 17(2): 97-111. [DOI:10.1038/nri.2016.107]

24. Emens LA (2016) Chemotherapy and tumour immunity: an unexpected collaboration. Cancer Immunol Res, 4(5): 379-380.

25. Forde PM, Chaft JE, Smith KN, et al. (2018) Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med, 378(21): 1976-1986. [DOI:10.1056/NEJMoa1716078]

26. Kato K, Sun JM, Shah MA, et al. (2022) Neoadjuvant nivolumab plus chemotherapy in resectable oesophageal cancer: 3-year follow-up of the multicenter, randomized phase 3 CheckMate 577 trial. Lancet Oncol, 23(1): 115-127.

27. Patel TD, Hinni ML, Hayden RE, et al. (2018) Neoadjuvant therapy for sinonasal malignancies: institutional outcomes and predictors of survival. Head Neck. 40(7):1501-1509.

28. Abiri A, Chernock RD, Lin J, et al (2023) Chemo-immunotherapy for advanced sinonasal carcinoma: early single-institution experience. Oral Oncol, 140: 106347.

29. Daly ME and Chen AM (2020) Radiotherapy for sinonasal cancer: contemporary approaches and future directions. Curr Oncol Rep, 22(7): 53.

30. Llorente JL, López F, Suárez C, et al. (2014) Sinonasal carcinoma: clinical and pathological advances. Cancer Treat Rev, 40(1): 19-26.

31. Sun Y, Yang G, Sun R, et al. (2024) Neoadjuvant immunotherapy plus chemotherapy for squamous cell carcinoma of the paranasal sinus: a case report. Front. Oncol, 14: 1462993. [DOI:10.3389/fonc.2024.1462993]

32. Wen Y, Huang Y, Luo W, et al. (2025) Comparative study on the clinical efficacy and quality of life of helical tomotherapy and three-dimensional conformal radiotherapy for locally advanced nasopharyngeal carcinoma. Int J Radiat Res, 23(2): 18. [DOI:10.61186/ijrr.23.2.18]

33. Miller KD, Nogueira L, Devasia T, et al. (2022) Cancer treatment and survivorship statistics. CA Cancer J Clin, 72(5): 409-436. [DOI:10.3322/caac.21731]

34. Van Gerven L, Kruse A, Vermorken JB (2021) Challenges in the management of sinonasal cancers: a multidisciplinary perspective. Lancet Oncol, 22(7): e273-e285.

35. Abdelmeguid AS, Teeramatwanich W, Roberts DB, et al. (2021) Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses. Cancer, 127(11): 1788-1795. [DOI:10.1002/cncr.33452]

36. Zhang Z, He W, Yang L, et al. (2021) Dosimetric comparison between the use of insertion needles and fletcher applicator in brachytherapy for cervical cancer. Int J Radiat Res, 19(4): 819-827. [DOI:10.52547/ijrr.19.4.7]

37. Hafström A, Sjövall J, Persson SS, et al. (2022) Outcome for sinonasal malignancies: a population-based survey. Eur Arch Otorhinolaryngol, 279(5): 2611-2622. [DOI:10.1007/s00405-021-07057-0]

38. Ferrari M, Taboni S, Carobbio ALC, et al. (2021) Sinonasal squamous cell carcinoma, a narrative reappraisal of the current evidence. Cancers (Basel), 13(11): 2835. [DOI:10.3390/cancers13112835]

39. Schoenfeld JD, Margalit DN, Cash E, et al. (2020) Immunotherapy and radiation therapy for head and neck cancer: current evidence and future directions. J Natl Compr Canc Netw, 18(6): 874-880.

40. Masarwy R, Kampel L, Horowitz G, et al. (2021) Neoadjuvant PD-1/PD-L1 inhibitors for resectable head and neck cancer: A systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg, 147(10): 871-878. [DOI:10.1001/jamaoto.2021.2191]

41. Ferris RL, Fakhry C, et al. (2021). Immunotherapy for head and neck cancer: a paradigm shift from induction chemotherapy to neoadjuvant immunotherapy. Cancer J, 27(2): 134-142.

42. Ferris RL, Blumenschein G, Fayette J, et al. (2021) Checkpoint inhibitors in combination with chemotherapy in head and neck squamous cell carcinoma. Clin Cancer Res, 27(14): 3839-3850.

43. Pfister DG, Spencer S, Adelstein D, et al. (2022) Head and neck cancers, version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 20(3): 224-240.

44. Chung JH, Oxnard GR, Cooper JT, et al. (2021) Predictive value of PD-L1 and TMB in head and neck cancer: a multi-institutional analysis. Cancer Immunol Res, 9(12): 1341-1352.

45. Ok VC, Lai J, Patil P, et al. (2023) Immunogenic cell death and its role in enhancing immunotherapy response. Front Oncol, 13: 1209831.

46. Ghobadi A, Kato K, Chumsri S, et al. (2021) Biomarker-driven immunotherapy in head and neck cancers. Cancers (Basel), 13(11): 2722. [DOI:10.3390/cancers13236041]

47. Bhattasali O, Holliday E, Kies MS, et al. (2022) Proton therapy outcomes in sinonasal malignancies: evidence and emerging indications. Radiother Oncol, 173: 34-41.

48. Romesser PB, Cahlon O, Scher E, et al. (2021) Multi-institutional outcomes of proton therapy for skull base and sinonasal tumors. Acta Oncol, 60(9): 1140-1148.

49. Schoenfeld JD (2020) Mechanistic basis of radiation and immunotherapy synergy. Int J Radiat Oncol Biol Phys, 108(1): 3-14.

50. Li X, Wan Z, Liu X, et al. (2022) A 12-chemokine gene signature is associated with the enhanced immunogram scores and is relevant for precision immunotherapy. Med. Oncol, 39(4): 43. [DOI:10.1007/s12032-021-01635-2]

51. Chandran SS, Sahu A, Saberian NH, et al. (2022) Neoadjuvant checkpoint blockade reshapes the tumour microenvironment in solid tumours. Sci Transl Med, 14(661): eabg7539.

52. Patel SG, Singh H, Roman BR, et al. (2023) Future directions in sinonasal cancer: precision oncology and immune-based approaches. Curr Opin Otolaryngol Head Neck Surg, 31(2): 75-83.